ArticleEmerging infectious diseases2023
Case of Carbapenem-Resistant Salmonella Typhi Infection, Pakistan, 2022.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Identification and Genomic Analysis of the First Salmonella typhimurium Monophasic Variant 1,4,[5],12:i:- Isolate Harbouring a Chromosomally Integrated blaMicrobial biotechnology · 2026Article
- Emergence of blaBMC microbiology · 2026Article
- Multi-omics analysis of glycolytic reprogramming and ROS dynamics in host-specific responses to Salmonella Typhi infection in mice.Journal of advanced research · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- ConfrontingInfection and drug resistance · 2026Review
- Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance.Interdisciplinary perspectives on infectious diseases · 2026Review
- AMRrounds: What goes around comes back around-recurrent KPC-producingJAC-antimicrobial resistance · 2025Article
- Carbapenem-Resistant Salmonella Typhi Infection in Traveler Returning to Germany from India, 2024.Emerging infectious diseases · 2025Article
- Typhi Mykrobe: fast and accurate lineage identification and antimicrobial resistance genotyping directly from sequence reads for the typhoid fever agent Salmonella Typhi.Genome medicine · 2025Article
- Comprehensive analysis of extensive drug-resistantMicrobiology spectrum · 2025Article
- Changes in enteric fever trends during the COVID-19 pandemic from the Surveillance for Enteric Fever in Asia Project: a cross-sectional study.The Lancet regional health. Southeast Asia · 2025Article
- Emergence of carbapenem-resistantFrontiers in microbiology · 2025Article
- Azithromycin-resistant mph(A)-positive Salmonella enterica serovar Typhi in the United States.Journal of global antimicrobial resistance · 2024Article
- Trends in antimicrobial resistance amongst Salmonella Typhi in Bangladesh: A 24-year retrospective observational study (1999-2022).PLoS neglected tropical diseases · 2024Observational
- The origins of haplotype 58 (H58) Salmonella enterica serovar Typhi.Communications biology · 2024Article
- Exploring the antimicrobial efficacy of Manuka honey against multidrug-resistant and extensively drug-resistantFuture microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella Typhi infection in a patient in Pakistan initially responded to standard treatment but failed to respond to subsequent treatment. The first strain was susceptible to carbapenems and azithromycin; subsequent strains harbored the NDM-5 gene. Treatment with a combination of intravenous meropenem and colistin was successful. Carbapenem-resistant Salmonella Typhi emergence will hinder treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.